FORMA THERAPEUTICS HOLDINGS, INC.

Inactive Instrument

Analyst Reco. Forma Therapeutics Holdings, Inc.

Equities

FMTX

US34633R1041

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Credit Suisse Downgrades Forma Therapeutics Holdings to Neutral from Outperform Following News of Novo Nordisk Acquisition, Lowers Price Target to $20 from $33	02/09/22	MT
HC Wainwright Downgrades Forma Therapeutics Holdings to Neutral From Buy, Adjusts Price Target to $20 From $53	02/09/22	MT
Jefferies Downgrades Forma Therapeutics Holdings to Hold From Buy, Adjusts Price Target to $20 From $28	02/09/22	MT
Cantor Fitzgerald Downgrades Forma Therapeutics to Neutral From Overweight, Trims Price Target to $20 From $23	01/09/22	MT
Cantor Fitzgerald Assumes Forma Therapeutics Holdings at Overweight with $21 Price Target	13/06/22	MT
SVB Securities Lowers Forma Therapeutics Holdings' Price Target to $23 From $25, Maintains Outperform Rating	27/05/22	MT
Oppenheimer Adjusts Price Target on Forma Therapeutics Holdings to $46 From $49, Maintains Outperform Rating	27/05/22	MT
Oppenheimer Adjusts Forma Therapeutics Holdings Price Target to $49 From $60, Maintains Outperform Rating	02/03/22	MT
Credit Suisse Raises Forma Therapeutics Holdings' Price Target to $66 from $62, Maintains Outperform Rating	14/02/22	MT
FORMA THERAPEUTICS : HC Wainwright Adjusts Price Target on Forma Therapeutics Holdings to $53 From $55, Keeps Buy Rating	17/08/21	MT
FORMA THERAPEUTICS : Craig-Hallum Starts Forma Therapeutics Holdings at Buy With $58 Price Target	02/08/21	MT
FORMA THERAPEUTICS : SVB Leerink Adjusts Forma Therapeutics Holdings PT to $54 From $65, Maintains Outperform Rating	11/06/21	MT
FORMA THERAPEUTICS : HC Wainwright Adjusts Forma Therapeutics Holdings' Price Target to $55 From $53, Keeps Buy Rating	31/03/21	MT
FORMA THERAPEUTICS : Oppenheimer Initiates Coverage on Forma Therapeutics Holdings With Outperform Rating, $60 Price Target	17/02/21	MT
FORMA THERAPEUTICS : Cantor Fitzgerald Adjusts Price Target on Forma Therapeutics Holdings to $68 From $61, Maintains Overweight Rating	08/12/20	MT
FORMA THERAPEUTICS : Credit Suisse Adjusts Forma Therapeutics' Price Target to $68 from $64, Keeps Outperform Rating	08/12/20	MT
FORMA THERAPEUTICS : SVB Leerink Adjusts Forma Therapeutics' Price Target to $65 from $54, Keeps Outperform Rating	08/12/20	MT
FORMA THERAPEUTICS : Cantor Fitzgerald Starts Forma Therapeutics at Overweight With $61 Price Target	19/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer